

This week in therapeutics

| Indication | Target/marker/ pathway | Summary | Licensing status | Publication and contact information |
|------------------|---|--|--|---|
| Neurology | | | | |
| Pain | Neuronal nitric oxide synthase 1 (NOS1; nNOS) | <p>Rat and tissue culture studies identified 3,6-disubstituted indole derivative-based nNOS inhibitors that could help treat neuropathic pain. In a rat model of neuropathic pain, the lead nNOS inhibitor decreased thermal hyperalgesia compared with baseline. Next steps include evaluating the pharmacology and toxicology of the nNOS inhibitors.</p> <p>NXN-188, a small molecule nNOS inhibitor and serotonin (5-HT) receptor agonist from NeurAxon Inc., is in Phase II testing to treat migraines. The company has three additional nNOS inhibitors in preclinical development for pain and migraine.</p> <p><i>SciBX</i> 4(39); doi:10.1038/scibx.2011.1093 Published online Oct. 6, 2011</p> | <p>Patented; available for licensing from NeurAxon Contact: John S. Andrews, NeurAxon Inc., Mississauga, Ontario, Canada phone: 416-673-6697 e-mail: jandrews@neuraxon.com</p> | <p>Annedi, S.C. <i>et al. J. Med. Chem.</i>; published online Sept. 16, 2011; doi:10.1021/jm201063u Contact: Subhash C. Annedi, NeurAxon Inc., Mississauga, Ontario, Canada e-mail: sannedi@neuraxon.com</p> |